Treatment Landscape and Unmet Needs in Advanced Gastric Cancers

Opinion
Video

Panelists discuss how advanced gastric cancer treatments currently include surgery, chemotherapy (primarily platinum/fluoropyrimidine combinations), targeted therapies (trastuzumab for HER2-positive disease, ramucirumab), and immunotherapy (pembrolizumab and nivolumab in select patients). Despite these options, major unmet needs persist, with low survival rates, lack of predictive biomarkers beyond HER2, limited effective treatments after first-line therapy, poor response rates to immunotherapy, and high treatment toxicity affecting quality of life. Many patients also present with late-stage disease due to delayed diagnosis.

CN25_BTL_UGI_Seg01_Treatment
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Video content above is prompted by the following:

      • Briefly discuss the current treatment landscape for advanced gastric cancers.
      • What are some unmet needs in this patient population?
      Recent Videos
      4 experts in this video
      Imaging Quality in Prostate Cancer: Impact on Treatment Decision-Making
      Exploring Next-Line Options: Therapies Beyond Trastuzumab Deruxtecan in HER2+ MSS Gastric Cancer
      Exploring Next-Line Options: Therapies Beyond Trastuzumab Deruxtecan in HER2+ MSS Gastric Cancer
      4 experts in this video
      Selecting the Optimal PSMA PET Imaging Agent: Clinical Considerations and Data-Driven Decisions
      3 experts are featured in this series.
      Second-Line Treatment for Gastric Adenocarcinoma
      3 experts are featured in this series.
      Advanced Metastatic Gastric Adenocarcinoma: Treatment Approaches
      3 experts are featured in this series.
      Gastric Adenocarcinoma: Current Treatment Landscape
      3 experts are featured in this series.
      Adjuvant Nivolumab in Gastric Cancers & CheckMate 8HW
      3 experts are featured in this series.
      Esophageal/Gastric Adenocarcinoma Standard of Care
      2 experts are featured in this series.
      BESPOKE: Study Design, Efficacy End Points and Methods
      2 experts are featured in this series.
      The Role of ctDNA in CRC
      Related Content
      Nivolumab-based therapies showed improved efficacy vs chemotherapy in hypermutated and Epstein-Barr virus–positive gastroesophageal tumors.

      Various Mechanisms May Inform Nivolumab Use in Gastroesophageal Cancer

      Roman Fabbricatore
      March 23rd 2025
      Article

      Nivolumab-based therapies showed improved efficacy vs chemotherapy in hypermutated and Epstein-Barr virus–positive gastroesophageal tumors.

      Immunotherapy Treatments Only Just Emerging in Esophageal, Gastric Cancers

      Immunotherapy Treatments Only Just Emerging in Esophageal, Gastric Cancers

      Geoffrey Y. Ku, MD
      January 18th 2017
      Podcast

      Ahead of the 2017 ASCO Gastrointestinal Cancer Symposium in San Francisco, we spoke with Dr. Geoffrey Ku on the advances in systemic therapy for esophageal and gastric cancer.

      Phase 3 data support ramucirumab/paclitaxel switch maintenance as a post-induction therapy for patients who are not eligible for immunotherapy.

      Ramucirumab Maintenance Combo Shows Benefit in HER2– Gastric/GEJ Cancer

      Russ Conroy
      March 17th 2025
      Article

      Phase 3 data support ramucirumab/paclitaxel switch maintenance as a post-induction therapy for patients who are not eligible for immunotherapy.

      Updated Nivolumab Data Solidify Use in Advanced Gastric/GEJ/Esophageal Cancers

      Updated Nivolumab Data Solidify Use in Advanced Gastric/GEJ/Esophageal Cancers

      ONCOLOGY Staff
      March 14th 2025
      Article

      Results from the CheckMate649 trial support the use of nivolumab plus chemotherapy in the treatment of advanced gastric cancers.

      Data from the MATTERHORN trial show a trend towards improved overall survival with the durvalumab combination in gastric and GEJ cancers.

      Durvalumab Combo Meaningfully Improves EFS in Advanced Gastric/GEJ Cancer

      Russ Conroy
      March 7th 2025
      Article

      Data from the MATTERHORN trial show a trend towards improved overall survival with the durvalumab combination in gastric and GEJ cancers.

      The safety profile of trastuzumab deruxtecan in the phase 3 DESTINY-Gastric04 trial was consistent with the established safety profile of the agent.

      Trastuzumab Deruxtecan Improves Survival in HER2+ Metastatic Gastric Cancer

      Roman Fabbricatore
      March 5th 2025
      Article

      The safety profile of trastuzumab deruxtecan in the phase 3 DESTINY-Gastric04 trial was consistent with the established safety profile of the agent.